Compounds > isocoumarin nm-3
Page last updated: 2024-12-11

isocoumarin nm-3

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

isocoumarin NM-3: a synthetic derivative of cytogenin; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5493470
SCHEMBL ID3191297
MeSH IDM0422491

Synonyms (22)

Synonym
isocoumarin nm-3
2-(8-hydroxy-6-methoxy-1-oxoisochromen-3-yl)propanoic acid
unii-5797k23f95
nm-3
nm 3 (isocoumarin)
5797k23f95 ,
8-hydroxy-6-methoxy-alpha-methyl-1-oxo-1h-2-benzopyran-3-acetic acid
nm 3
181427-78-1
2-(8-hydroxy-6-methoxy-1-oxo-1h-isochromen-3-yl)propionic acid
1h-2-benzopyran-3-acetic acid, 8-hydroxy-6-methoxy-alpha-methyl-1-oxo-
1h-2-benzopyran-3-acetic acid, 8-hydroxy-6-methoxy-.alpha.-methyl-1-oxo-
SCHEMBL3191297
2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid
2-(8-hydroxy-6-methoxy-1-oxo-1h-isochromen-3-yl)propanoic acid
nm-3 (isocoumarin)
AKOS030619018
DB12818
FT-0717128
2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl)propanoic acid
DTXSID10939433
Q27261487

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" The present work has assessed the activity of NM-3 against human non-small-cell lung cancer (NSCLC) cells when used alone and in combination with docetaxel."( The angiogenesis inhibitor NM-3 is active against human NSCLC xenografts alone and in combination with docetaxel.
Agata, N; Bamberg, M; Kharbanda, S; Kufe, D; Milhollen, M; Nogi, H; Pu, M; Weitman, S, 2005)		0.33
"To investigate the effects of 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid (NM-3) alone and in combination with carboplatin on tumor growth and apoptosis in mouse models of human gastric cancer constructed by subcutaneous implantation of histologically intact tumor tissue."( Effect of 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid in combination with carboplatin on gastric carcinoma growth in vivo.
Chen, JL; Chen, MX; Chen, NW; Chen, WX; Hong, J; Lu, JL; Shen, B; Zhu, JS; Zhu, ZM, 2007)		0.34
" NM-3 was injected peritoneally at the dose of 10 mg/kg, 20 mg/kg or 40 mg/kg every other day for 5 wk, combined with carboplatin (5 mg/kg) every third day for 4 wk."( Effect of 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid in combination with carboplatin on gastric carcinoma growth in vivo.
Chen, JL; Chen, MX; Chen, NW; Chen, WX; Hong, J; Lu, JL; Shen, B; Zhu, JS; Zhu, ZM, 2007)		0.34
" But NM-3 in combination with carboplatin had greater effects of tumor weight than either NM-3 or carboplatin alone."( Effect of 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid in combination with carboplatin on gastric carcinoma growth in vivo.
Chen, JL; Chen, MX; Chen, NW; Chen, WX; Hong, J; Lu, JL; Shen, B; Zhu, JS; Zhu, ZM, 2007)		0.34
" Furthermore, NM-3 alone at the dose of 10 mg/kg or in combination with carboplatin has no obvious effects on body changes, indicating that NM-3 in combination with carboplatin may be effective in the treatment of gastric cancer."( Effect of 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid in combination with carboplatin on gastric carcinoma growth in vivo.
Chen, JL; Chen, MX; Chen, NW; Chen, WX; Hong, J; Lu, JL; Shen, B; Zhu, JS; Zhu, ZM, 2007)		0.34

Bioavailability

ExcerptReferenceRelevance
" The bioavailability and nontoxic profile of NM-3 suggests that the efficacy of this agent should be tested in clinical radiotherapy."( NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity.
Beckett, MA; Gupta, VK; Hari, DM; Hellman, S; Jaskowiak, NT; Kalluri, R; Koons, AM; Kufe, DW; Mauceri, HJ; Posner, MC; Reimer, C; Salloum, RM; Seetharam, S; Weichselbaum, RR, 2000)		0.31
"2-(8-Hydroxy-6-methoxy-1-oxo-1Eta-2-benzopyran-3-yl)propionic acid (NM-3) is a small molecule isocoumarin derivative that has recently entered clinical trials as an orally bioavailable anticancer agent."( 2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic acid, a small molecule isocoumarin, potentiates dexamethasone-induced apoptosis of human multiple myeloma cells.
Agata, N; Kharbanda, S; Kufe, D; Milhollen, M; Nogi, H, 2004)		0.32
"The novel isocoumarin 2-(8-hydroxy-6-methoxy-1-oxo-1 H-2-benzopyran-3-yl) propionic acid (NM-3) has completed phase I clinical evaluation as an orally bioavailable angiogenesis inhibitor."( The angiogenesis inhibitor NM-3 is active against human NSCLC xenografts alone and in combination with docetaxel.
Agata, N; Bamberg, M; Kharbanda, S; Kufe, D; Milhollen, M; Nogi, H; Pu, M; Weitman, S, 2005)		0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (6.67)18.2507
2000's14 (93.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.26 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.0110nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.4220taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
isocoumarins
Isocoumarins: Compounds that differ from COUMARINS in having the positions of the ring and ketone oxygens reversed so the keto oxygen is at the 1-position of the molecule.. isocoumarin : The simplest member of the class of isocoumarins that is 1H-isochromene which is substituted by an oxo group at position 1.		4.09150isocoumarins
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		2.0210secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
carboplatin
[no description available]		2.4320
cytogenin
[no description available]		2.730
cytochrome c-t
Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.		2.0210
oxymatrine
oxymatrine: structure in first source; has anti-apoptosis effects		2.0310
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		3.6290benzenes;
hydroxycoumarin;
methyl ketone
transforming growth factor beta
Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.		2.0310
ConditionIndicatedRelationship StrengthStudiesTrials
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		0210
Cancer of Stomach
[description not available]		02.9440
Stomach Neoplasms
Tumors or cancer of the STOMACH.		02.9440
Kahler Disease
[description not available]		02.4320
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		02.4320
Carcinoma, Non-Small Cell Lung
[description not available]		02.0210
Cancer of Lung
[description not available]		02.0210
Experimental Neoplasms
[description not available]		02.0210
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.0210
Lung Neoplasms
Tumors or cancer of the LUNG.		02.0210
Diabetes Mellitus, Adult-Onset
[description not available]		02.0310
Diabetic Glomerulosclerosis
[description not available]		02.0310
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		02.0310
Diabetic Nephropathies
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.		02.0310
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		02.0310
Angiogenesis, Pathologic
[description not available]		02.9340
Adenocarcinoma, Basal Cell
[description not available]		02.4220
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0310
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.4220
Sarcoma 180
An experimental sarcoma of mice.		0210
Carcinoma, Lewis Lung
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.		0210
Cancer of Esophagus
[description not available]		0210
Benign Neoplasms
[description not available]		0210
Esophageal Neoplasms
Tumors or cancer of the ESOPHAGUS.		0210
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		0210
Polyarthritis
[description not available]		0210
Arthritis
Acute or chronic inflammation of JOINTS.		0210
Breast Cancer
[description not available]		02.0110
Cancer of Prostate
[description not available]		02.0110
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0110
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.0110